



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



SET, Phosphatase 2A Inhibitor I2PP2A. Rabbit Antigen Immunoaffinity Purified Polyclonal

BACKGROUND

Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression are found in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.

IMMUNOGEN

Synthetic peptide derived from the human SET protein

POSITIVE CONTROL/TISSUE EXPRESSION

Widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.

COMMENTS

Antibody can be used for Western blotting (1:400 dilution). Optimal concentration should be evaluated by serial dilutions.

ORDERING INFORMATION

CATALOG NUMBER

X2332P

SIZE

10 Miniblots

FORM

Affinity Purified

HOST/CLONE

Rabbit

FORMULATION

Provided as solution in phosphate buffered saline with 0.08% sodium azide

CONCENTRATION

Lot specific, see vial

ISOTYPE

IgG

APPLICATIONS

Western Blot

SPECIES REACTIVITY

Human

ACCESSION NUMBER

Q01105, Human

PURIFICATION

Antigen Immunoaffinity Purification

SHIP CONDITIONS

Ship on gel ice, store at -20°C immediately upon arrival

STORAGE CUSTOMER

Product should be stored at -70°C. Aliquot to avoid freeze/thaw cycles

STABILITY

Products are stable for one year from purchase when stored properly

REFERENCES

- [1] von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., Grosveld G.; Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.; *Mol. Cell. Biol.* 12:3346-3355(1992).
- [2] von Lindern M., van Baal S., Wiegant J., Raap A., Hagemeijer A., Grosveld G.; Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.; *Mol. Cell. Biol.* 12:3346-3355(1992).
- [3] Vaesen M., Barnikol-Watanabe S., Goetz H., Adil Awni L., Cole T., Zimmermann B., Kratzin H.D., Hilschmann N.; Purification and characterization of two putative HLA class II associated proteins: PHAPI and PHAPII.; *Biol. Chem. Hoppe-Seyler* 375:113-126(1994).
- [4] Nagata K., Kawase H., Handa H., Yano K., Yamasaki M., Ishimi Y., Okuda A., Kikuchi A., Matsumoto K.; Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis.; *Proc. Natl. Acad. Sci. U.S.A.* 92:4279-4283(1995).
- [5] Li M., Makkinje A., Damuni Z.; The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A.; *J. Biol. Chem.* 271:11059-11062(1996).
- [6] Tsujio I., Zaidi T., Xu J., Kotula L., Grundke-Iqbal I., Iqbal K.; Inhibitors of protein phosphatase-2A from human brain: structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated Tau.; Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
- [7] The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; *Genome Res.* 14:2121-2127(2004).
- [8] Adachi Y., Pavlaki G.N., Copeland T.D.; Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.; *J. Biol. Chem.* 269:2258-2262(1994).
- [9] Wang L.C., Chen Y.; A relative factor in human rectum carcinoma.; Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
- [10] Carlson S.G., Eng E., Kim E.-G., Perlman E.J., Copeland T.D., Ballermann B.J.; Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.; *J. Am. Soc. Nephrol.* 9:1873-1880(1998).
- [11] Seo S.-B., McNamara P., Heo S., Turner A., Lane W.S., Chakravarti D.; Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the Set oncoprotein.; *Cell* 104:119-130(2001).
- [12] Minakuchi M., Kakazu N., Gorrin-Rivas M.J., Abe T., Copeland T.D., Ueda K., Adachi Y.; Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.; *Eur. J. Biochem.* 268:1340-1351(2001).
- [13] Fan Z., Beresford P.J., Zhang D., Lieberman J.; HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A.; *Mol. Cell. Biol.* 22:2810-2820(2002).
- [14] Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J.; Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor.; *Cell* 112:659-672(2003).
- [15] Fan Z., Beresford P.J., Oh D.Y., Zhang D., Lieberman J.; *Cell* 115:241-241(2003).
- [16] Olsen J.V., Blagoev B., Gnäd F., Macek B., Kumar C., Mortensen P., Mann M.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; *Cell* 127:635-648(2006).
- [17] Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.; Substrate and functional diversity of lysine acetylation revealed by a proteomics survey.; *Mol. Cell* 23:607-618(2006).
- [18] Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.; Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry.; *Proc. Natl. Acad. Sci. U.S.A.* 104:2199-2204(2007).